Ann: Paradigm Appoints Experienced US-Based CEO, page-64

This thread has been a good read, I enjoy the thoughts of you guys.

Yes of course 008 is pivotal, it puts us in that class, that cut above...

BUT imagine it was shown that Pentosan (the iPPS version) wasn't DMOAD...



What have we got left then?


1) A drug that reduces pain at least as much as the *cough* std of care


2) A drug that increases functionality by at least as much as anything that's remotely the std of care


3) A drug that is natural based...but is SAFE...years of safety data....NO Serious Adverse Effects


4) All of the above would not be as glittery (err... nice) of a selling point if you need top ups every 6 hours.....ie. DURABILITY...a drug that works and stays working for a good amount of time, possibly up to 9 - 12 months for the average? (Subject to confirmation)


5) Ahh all of the above great Mozz but the prospective new CEO wouldn't be all that interested despite the above IF the drug was easily reproduceable? Its extremely hard to exactly replicate.


6) Added bonus, iPPS is stable at room temp. No messy transport issues, no fridge required, stable molecule



7) Oh go on - ONE more bonus...OA and the various MOA is not the only thing here...we are seeing pain reduction...think outside OA...116 million Americans in pain RIGHT now as I type this...don't you think there is some off label chance here?




So I agree with you, 008 is very important, yes...but without it, in just my humble view, it just ain't no show stopper.





Marco knows all of the above.



DYOR